Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion) is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||28/10/2020|
|Rapid review completed||18/12/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amikacin sulfate (Arikayce® liposomal nebuliser dispersion (ALND) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies|
|Full pharmacoeconomic assessment commissioned by HSE||04/01/2022|
|Full HTA Submission received from Applicant||01/04/2022|
|Current Status||Full HTA submission received from Applicant|